Hexarelin
Synthetic hexapeptide growth-hormone secretagogue developed in the 1990s. Stimulates GH release potently in short-term human studies. Concerns about tachyphylaxis (tolerance) with chronic use have limited clinical development.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
What the research shows
1990s/2000s short-term studies show robust GH/IGF-1 elevation in healthy adults. Some research interest in cardiac protection (preclinical). No modern Phase 3 trials in humans. Not pursued to FDA approval.
What's still experimental
Tachyphylaxis management, optimal cycling protocols, long-term safety, and any modern indication-specific human RCTs.
Anecdotal / community reports
Bodybuilding and 'optimization' communities use hexarelin in cycles. Reports of strength/recovery improvements are uncontrolled and confounded by other interventions.
Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.
FDA approval status
Source: openFDA + DailyMed (NIH/NLM)Doses studied in research
No established dose rangeWhat published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.
This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.
FDA enforcement & recalls
Live · openFDA Drug Enforcement APIMechanism & targets
ChEMBL · UniProt · Open TargetsMolecule (ChEMBL)
View on ChEMBLLive research
PubMed · ClinicalTrials.gov · Europe PMC · OpenAlexEurope PMC — 562 additional records
Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future PerspectivesRenke G, Chinellato L. · 2026Open access
- Ghrelin Receptor Deletion or Pharmacological Inhibition Improves Muscle Function in Aging Male MiceKerr HL, Krumm K, Myree N, et al. · 2026Open access
- Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease modelsPedrolli F, Morello G, Gesmundo I, et al. · 2026Open access
- Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025Thevis M, Kuuranne T, Geyer H., et al. · 2026Open access
Research volume (OpenAlex topic graph)
Human clinical evidence
Semantic Scholar · AI TLDRs · influence-rankedMost influential human studies
- Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in ratsJournal articleOpen access1 influential / 26 citedD. Dahlgren, Tobias Olander, M. Sjöblom · Acta Pharmaceutica Sinica B · 2021
TLDR The data in this study suggests that the potential for paracellular permeability enhancers to increase intestinal absorption of hydrophilic peptides with low molecular mass is greater than for those with transcellular mechanism-of-action.
- Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexiaJournal articleOpen access1 influential / 43 citedGiuseppe Sirago, E. Conte, F. Fracasso · Scientific Reports · 2017
TLDR Findings reveal a key-role played by mitochondria in the mechanism responsible for GHS beneficial effects in skeletal muscle, strongly indicating that targeting mitochondrial dysfunction might be a promising area of research in developing therapeutic strategies to prevent or limit muscle wasting in cachexia.
- The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway.Journal articleOpen access1 influential / 19 citedJiannan Huang, Yi Li, Juan Zhang · International Heart Journal · 2017
TLDR It is suggested that hexarelin protects in vivo cardiomyocytes from I/R injury partly by modification of the IL-1 signaling pathway through the activation of cardiac GHSR1a receptors.
- Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin‐Resistant Male MKR MiceJournal articleOpen access1 influential / 10 citedRasha Mosa, Li-li Huang, Yeda Wu · Endocrinology · 2017
TLDR Hexarelin treatment corrected the abnormal body composition of MKR mice, as demonstrated by a decrease in fat mass and an increase in lean mass, suggesting a possible application of hexarelin in treatment of lipid disorders associated with the metabolic syndrome.
- Hexarelin modulates stress effects on ghrelin system activity in growing lambsJournal articleOpen accessK. Pierzchała-Koziec, C. G. Scanes, Alina Gajewska, et al. · Folia Biologica · 2024
Research funding & verification
NIH RePORTER · CrossRef DOI registryNIH-funded research
U.S. National Institutes of Health- 1R01HL082511-01$464KThe role of CD36 in ischemic inflammation and injurySunghee Cho · WINIFRED MASTERSON BURKE MED RES INST · FY2006
- 5R01HL082511-03$451KThe role of CD36 in ischemic inflammation and injurySunghee Cho · WINIFRED MASTERSON BURKE MED RES INST · FY2008
- 5R01HL082511-05$451KThe role of CD36 in ischemic inflammation and injurySunghee Cho · WINIFRED MASTERSON BURKE MED RES INST · FY2010
- 5R01HL082511-02$451KThe role of CD36 in ischemic inflammation and injurySunghee Cho · WINIFRED MASTERSON BURKE MED RES INST · FY2007
Publication landscape
CrossRef · DOI registry- University of Queensland3 works
- National Health and Medical Research Council3 works
- Università degli Studi di Milano-Bicocca2 works
- National Natural Science Foundation of China2 works
- Ministero dell’Istruzione, dell’Università e della Ricerca2 works
- Australian Postgraduate Award2 works
Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.
Preprints — cutting edge
bioRxiv · medRxiv · via Europe PMCPreprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.
- PreprintInvestigating the impact of COVID-19 on performance and image enhancing drug useDunn M, Piatkowski T. · 2021-07-29
- PreprintHexarelin exerts neuroprotective and antioxidant effects against hydrogen peroxide-induced toxicity through the modulation of MAPK and PI3K/Akt patways in Neuro-2A cellsMeanti R, Rizzi L, Bresciani E, et al. · 2020-11-16
Known risks
Tachyphylaxis (diminishing response with continued use) is well-documented. Theoretical cortisol and prolactin elevation. Cardiac effects (mostly positive in animal models) but human data is sparse. Source quality is a major concern — no FDA-approved formulations.
Reported side effects
Injection-site reactions, transient flushing, mild dizziness, possible water retention. Long-term effects poorly characterized in modern trials.
FDA adverse event reports (FAERS)
Updated quarterly by FDA- US1
Most-reported reactions
- Insomnia1
- Night Sweats1
Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs
What requires medical supervision
Not FDA-approved for any indication. Discuss with a clinician familiar with experimental peptides before considering. Source purity verification is essential.
Questions for your clinician
- Are there evidence-based alternatives (sermorelin, tesamorelin) that would address my goal?
- How would we monitor for tachyphylaxis and metabolic side effects?
- What's the exit criteria?